After reviewing this tutorial, participants should be able to define the term PET and explain the basic imaging principle of coincidence detection; should be able to explain how PET is different than other modalities; should be able to explain how PET radiopharmaceuticals display organ function rather than anatomy; what are the risks, benefits and clinical value of PET; should be able to name the PET pharmaceuticals available and their physical characteristics; should be able to relate the safety of these drugs; should be able to compare the radiation dose of F-18 FDG to that of other commonly used radiopharmaceuticals; should be able to recognize the chemical structures of FDG and glucose; should be able to discuss reimbursement issues and approved indications for F-18 FDG; and should be able to discuss use of this drug in oncology, neurology, and cardiology.